Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 1(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05075993Phase 1Active Not Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Role: collaborator

NCT04130542Phase 1Active Not Recruiting

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Role: lead

NCT04635995Phase 1Active Not Recruiting

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Role: lead

NCT05301764Phase 1Recruiting

A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma

Role: lead

NCT06378177Phase 2Recruiting

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Role: lead

NCT05152212Phase 1Completed

Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

Role: lead

NCT04694781Phase 1Completed

Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

Role: lead

All 7 trials loaded